Tau
BMS re-joins Alzheimer’s push, paying $80m for Prothena’s tau antibody
Phil Taylor
Alzheimer's disease, amyloid, antibody, Bristol-Myers Squibb, donanemab, Eli Lilly, neurology, Prothena, Tau
0 Comment
Biogen abandons tau antibody for Alzheimer’s after phase 2 miss
Phil Taylor
Alzheimer's disease, antibody, Biogen, central nervous system, neurology, Tau
0 Comment
Early data back J&J and AC Immune’s Alzheimer’s jab
Phil Taylor
AC Immune, Alzheimer's disease, Johnson & Johnson, neurology, Tau, vaccine
0 Comment
News/ News/ R&D/ Top stories
AC Immune poleaxed on Alzheimer’s study fail
Phil Taylor
AC Immune, Alzheimer's disease, Genentech, Roche, Tau
0 Comment
News/ News/ R&D/ Top stories
Roche doubles down on tau for Alzheimer’s, licensing UCB drug for $120m
Phil Taylor
Alzheimer's disease, licensing, neurology, Roche, Tau, UCB
0 Comment
R&D/ Views & Analysis/ Views and analysis
A bright future for CNS and Alzheimer’s?
George Underwood
Alzheimer's, amyloid, Asceneuron, CNS, progressive supranuclear palsy, Tau
0 Comment